Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/imt.15.75 http://scihub22266oqcxt.onion/10.2217/imt.15.75 C4681396!4681396!26598957     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunotherapy 2015 ; 7 (10): 1073-104 Nephropedia Template TP {{tp|p=26598957|t=2015. Overview of current immunotherapeutic strategies for glioma |pdf=|usr=}}{{26598957}} gab.com Text Overview of current immunotherapeutic strategies for glioma JO: Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=26598957 #FOAvip In the last decade, numerous studies of immunotherapy for malignant glioma (glioblastoma multiforme) have brought new knowledge and new hope for improving the prognosis of this incurable disease. Some clinical trials have reached Phase III, following positive outcomes in Phase I and II, with respect to safety and immunological end points. Results are encouraging especially when considering the promise of sustained efficacy by inducing antitumor immunological memory. Progress in understanding the mechanisms of tumor-induced immune suppression led to the development of drugs targeting immunosuppressive checkpoints, which are used in active clinical trials for glioblastoma multiforme. Insights related to the heterogeneity of the disease bring new challenges for the management of glioma and underscore a likely cause of therapeutic failure. An emerging therapeutic strategy is represented by a combinatorial, personalized approach, including the standard of care: surgery, radiation, chemotherapy with added active immunotherapy and multiagent targeting of immunosuppressive checkpoints. Twit Text FOAVip Overview of current immunotherapeutic strategies for glioma ????Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=26598957 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26598957 #FOAvip English Wikipedia <ref>{{Cite pmid|26598957}}</ref> Overview of current immunotherapeutic strategies for glioma #MMPMID26598957 Calinescu AA; Kamran N; Baker G; Mineharu Y; Lowenstein PR; Castro MG Immunotherapy 2015[Oct]; 7 (10): 1073-104 PMID26598957show ga In the last decade, numerous studies of immunotherapy for malignant glioma (glioblastoma multiforme) have brought new knowledge and new hope for improving the prognosis of this incurable disease. Some clinical trials have reached Phase III, following positive outcomes in Phase I and II, with respect to safety and immunological end points. Results are encouraging especially when considering the promise of sustained efficacy by inducing antitumor immunological memory. Progress in understanding the mechanisms of tumor-induced immune suppression led to the development of drugs targeting immunosuppressive checkpoints, which are used in active clinical trials for glioblastoma multiforme. Insights related to the heterogeneity of the disease bring new challenges for the management of glioma and underscore a likely cause of therapeutic failure. An emerging therapeutic strategy is represented by a combinatorial, personalized approach, including the standard of care: surgery, radiation, chemotherapy with added active immunotherapy and multiagent targeting of immunosuppressive checkpoints. äOverview of current immunotherapeutic strategies for glioma (epmc).pdf DeepDyve Pubget Overpricing